Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults
NCT06182124 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to learn about the safety and immune effects of a pneumococcal vaccine in adults. This vaccine can possibly provide protection against further pneumococcal disease. This study will happen in 4 stages: Stage 1 is seeking participants who are between 18 years to 49 years of age. The participants will receive 1 of 2 pneumococcal vaccine candidates (different formulations) or 20vPnC (Prevnar 20) as a single shot given into the upper arm muscle. Stage 2 will begin after participants have completed Stage 1, and a pneumococcal vaccine candidate has been decided. Stage 2 is seeking participants who are adults 50 years of age and older. The participants will receive the chosen pneumococcal vaccine candidate from Stage 1 or 20vPnC (Prevnar 20). The vaccines will be given as a single shot into the upper arm muscle. Stage 3 is seeking participants who are adults 50 years of age and older. The participants will receive the chosen pneumococcal vaccine candidate from Stage 1 or a licensed pneumococcal comparator vaccine. The vaccines will be given as a single shot into the upper arm muscle. Stage 4 is seeking participants who are adults 50 years of age and older. The participants will receive either one of three pneumococcal vaccine candidates or one of two licensed pneumococcal comparator vaccines. The vaccines will be given as a single shot into the upper arm muscle. Participants will take part in this study for about 6 months for Stage 1, Stage 3, and Stage 4 and 12 months for Stage 2. During this time participants will have from 2 to 4 clinic visits and 1 phone visit. At these clinic visits, participants will be asked if any side effects were experienced. The participants will also have to give blood samples during these clinic visits.
Conditions Studied
Interventions
- BIOLOGICAL 20-valent pneumococcal conjugate vaccine (20vPnC)
- BIOLOGICAL Multivalent Pneumococcal Vaccine - Formulation 1
- BIOLOGICAL Multivalent Pneumococcal Vaccine - Formulation 2
- BIOLOGICAL Licensed pneumococcal comparator vaccine
- BIOLOGICAL Multivalent Pneumococcal Vaccine - Formulation 3
Study Locations (18)
Texas
- Headlands Horizons LLC — Brownsville
- DM Clinical Research- Cyfair — Houston
- Clinical Trials of Texas, LLC dba Flourish Research — San Antonio
- IMA Clinical Research San Antonio — San Antonio
- Dynamed Clinical Research, LP d/b/a DM Clinical Research — Sugar Land
- DM Clinical Research — Tomball
- Dynamed Clinical Research, LP d/b/a DM Clinical Research — Tomball
Florida
- Alliance for Multispecialty Research, LLC — Doral
- Indago Research & Health Center, Inc — Hialeah
Tennessee
- AMR Clinical — Knoxville
- AMR Clinical — Knoxville
Georgia
- Clinical Research Atlanta — Stockbridge
Illinois
- Optimal Research — Peoria
Louisiana
- Alliance for Multispecialty Research, LLC — New Orleans
Michigan
- Headlands Research - Detroit — Southfield
New York
- Rochester Clinical Research, LLC — Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 558 participants |
| Start Date | 2023-12-20 |
| Est. Completion | 2026-05-23 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06182124
The ClinicalTrials.gov registry entry for NCT06182124 describes a study currently listed as active not recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 558 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Pneumococcal Disease appearing as the primary indexed condition, and to 5 interventions — of which 20-valent pneumococcal conjugate vaccine (20vPnC) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06182124 reports 18 study locations spanning 10 distinct geographic areas — top geographies include Texas, Florida, Tennessee. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06182124 about?
NCT06182124 is a clinical study titled "A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults". The purpose of this study is to learn about the safety and immune effects of a pneumococcal vaccine in adults. This vaccine can possibly provide protection against further pneumococcal disease. This study will happen in 4 stages: Stage 1 is seeking participants who are between 18 years to 49 years ...
What is the current status of trial NCT06182124?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 558 participants. The study started on 2023-12-20. Estimated completion is 2026-05-23.
What conditions does trial NCT06182124 study?
This clinical trial studies the following conditions: Pneumococcal Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06182124?
The interventions under investigation include: 20-valent pneumococcal conjugate vaccine (20vPnC) (BIOLOGICAL), Multivalent Pneumococcal Vaccine - Formulation 1 (BIOLOGICAL), Multivalent Pneumococcal Vaccine - Formulation 2 (BIOLOGICAL), Licensed pneumococcal comparator vaccine (BIOLOGICAL), Multivalent Pneumococcal Vaccine - Formulation 3 (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06182124?
This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06182124 being conducted?
This trial has 18 study locations across Florida, Georgia, Illinois, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.